Turbo 'Tox

Often lasting twice as long as any other neurotoxin on the market, Daxxify makes its US debut.

- CELIA ELLENBERG

Are you excited?” Ellen Marmur, MD, asks me, beaming f rom behind her mask, when I settle into a treatment room at her white-walled Upper East Side office on a cold winter afternoon. The Manhattanbased dermatologist has just returned from a weekend at Revance’s headquarters in Nashville, where the pharmaceutical company hosted about 80 cosmetic dermatologists and plastic surgeons for a series of intensive seminars on Daxxify, the latest neuromodulator to receive FDA approval for the treatment of the glabella, the frequently furrowed lines between the eyebrows. In the company’s clinical trials, “Daxi,” as Marmur refers to it, had shown median outcomes lasting six months—sometimes up to nine months— more than twice as long as any other botulinum product on the market. As a member of Daxxify’s scientific advisory board since 2018, Marmur was one of the first providers to receive the injectable, which is being marketed as “the future of aesthetics” since it began its slow rollout at the end of last year. Her enthusiasm is palpable. “We’ve seen so many things come and go,” Marmur continues, prepping a syringe. “But really this broke through the noise.”